Can a new drug combo curb devastating NMOSD Flare-Ups?
NCT ID NCT07738952
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This early-stage trial is testing whether adding the drug sivelestat to standard steroid therapy is safe and may help people during an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition that can cause vision loss and paralysis. Seven participants with an active NMOSD relapse will receive sivelestat as a continuous intravenous infusion for five days alongside steroids, then be monitored for 28 days. The main goal is to check safety and tolerability, while also exploring whether the combination improves neurological recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sivelestat sodium hydrate
- What this could lead to
- If it works, adding sivelestat to standard steroid treatment could help people recover better from acute NMOSD attacks, potentially reducing lasting disability.
- What could go wrong
- This is an early, small trial (7 participants) focused mainly on safety, so it may not prove effectiveness. There is also the possibility of side effects from the drug or the combination with steroids.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER ATTACK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.